## Near-complete response to low-dose ceritinib in recurrent infantile inflammatory myofibroblastic tumour

Abhenil Mittal<sup>1</sup>, Aarushi Gupta<sup>2</sup>, Sameer Rastogi<sup>1</sup>, Adarsh Barwad<sup>3</sup> and Swati Sharma<sup>2</sup> ecancer **15** 1213 (2021) https://doi.org/10.3332/ecancer.2021.1213

<sup>1</sup>Department of Medical Oncology, Dr Bhim Rao Ambedkar (BRA) Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India

<sup>2</sup>Department of Radiodiagnosis, ABVIMS and Dr RML Hospital, New Delhi 110001, India

<sup>3</sup>Department of Pathology, All India Institute of Medical Sciences, New Delhi 110029, India

Keywords: ceritinib, infant, inflammatory myofibroblastic tumour, low dose

The images published in this article were previously used by the authors in the article: Gupta A, Sharma S, and Mittal A *et al* (2021) **Recurrent infantile inflammatory myofibroblastic tumor of mesentery—case report and review of imaging findings** *Radiol Case Rep* **16**(3) 504–510 [doi:10.1016/j.radcr.2020.12.027].

The authors have copyright of the images; however, this was not referenced.

Correspondence to: Sameer Rastogi Email: <a href="mailto:samdoc\_mamc@yahoo.com">samdoc\_mamc@yahoo.com</a>

ecancer 2021, 15:1286 https://doi.org/10.3332/ecancer.2021.1286

Published: 13/09/2021 Received: 20/08/2021

Publication costs for this article were supported by ecancer (UK Charity number 1176307).

**Copyright:** © the authors; licensee ecancermedicalscience. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<u>http://</u> <u>creativecommons.org/licenses/by/4.0</u>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.